Aerobic Exercise During Chemotherapy Eases Fatigue and Boosts Quality of Life in Breast Cancer Patients

For millions of women undergoing chemotherapy for breast cancer, the crushing exhaustion known as cancer-related fatigue is one of the most relentless and disabling symptoms of treatment. Unlike ordinary tiredness, this fatigue does not resolve with rest, can persist for months or years after the last infusion, and erodes nearly every dimension of daily life, from the ability to work and care for family to the simple willingness to leave the house. A new systematic review and meta-analysis published in BMC Cancer now offers some of the clearest quantitative evidence to date that a surprisingly straightforward intervention, aerobic exercise delivered during chemotherapy itself, can meaningfully reduce this fatigue and improve health-related quality of life.

The study, conducted by researchers at Shanghai University of Sport and Fudan University Shanghai Cancer Center in China, pooled data from eleven randomized controlled trials encompassing 933 adult patients with breast cancer who were receiving chemotherapy. Randomized controlled trials are considered the gold standard for establishing causation because participants are assigned by chance to either an exercise intervention or a control condition, minimizing the confounding that plagues observational studies. By synthesizing the results of multiple trials in a meta-analysis, the researchers could estimate effects with far greater statistical precision than any single small trial could achieve, while also probing whether particular features of exercise programs, such as intensity, format, or supervision, mattered for outcomes.

The search strategy was appropriately exhaustive. The team combed PubMed, Embase, Web of Science, the Cochrane Library, and EBSCOhost from the inception of each database through February 2026, identifying trials that specifically tested aerobic exercise, activities such as walking, cycling, or structured cardio programs that raise heart rate and breathing, initiated during chemotherapy. The analysis focused on two patient-centered endpoints: cancer-related fatigue, typically measured with validated instruments such as the Brief Fatigue Inventory, the Multidimensional Fatigue Inventory, or the Functional Assessment of Chronic Illness Therapy-Fatigue scale, and health-related quality of life, commonly captured with tools like the EORTC QLQ-C30 and the Functional Assessment of Cancer Therapy-Breast questionnaire.

The headline findings are striking in their consistency. Aerobic exercise significantly reduced cancer-related fatigue compared with usual care or non-exercise control conditions, yielding a standardized mean difference of negative 0.38 with a 95 percent confidence interval spanning negative 0.63 to negative 0.12 and a p-value of 0.004. In the language of meta-analysis, a standardized mean difference expresses the effect in units of pooled standard deviations, allowing studies that used different fatigue scales to be combined; a value approaching 0.4 is conventionally interpreted as a small-to-moderate effect, which for a symptom as refractory as cancer-related fatigue is clinically meaningful. On the quality-of-life side, the benefit was even larger: aerobic exercise improved health-related quality of life with a standardized mean difference of 0.52 (95 percent confidence interval, 0.28 to 0.75; p less than 0.001), a moderate effect that approaches the threshold at which patients themselves typically notice a difference.

Crucially, the authors did not stop at pooling averages. They formally assessed the risk of bias in the included trials using the Cochrane Risk of Bias 2 tool, conducted sensitivity analyses to test whether any single study drove the results, evaluated publication bias, and rated the certainty of the evidence using the GRADE framework, which grades confidence in effect estimates from high to very low based on study limitations, inconsistency, indirectness, and imprecision. This layered approach matters because meta-analyses of exercise interventions in oncology are frequently hampered by small samples, heterogeneous programs, and unblinded outcome assessment, since patients and assessors cannot easily be blinded to whether someone is exercising.

One of the most practically important parts of the analysis is the exploration of how exercise-program characteristics might modify the benefit. Subgroup analyses suggested potentially greater reductions in fatigue and larger gains in quality of life with moderate-to-high intensity exercise, with continuous or composite aerobic formats, and with partially supervised interventions. However, the differences between these subgroups were not statistically significant, meaning the data cannot yet declare one program design superior to another. This is a common and often misunderstood nuance in evidence synthesis: subgroup point estimates can look compelling, but without significant between-group differences, they should be treated as hypothesis-generating rather than practice-changing. The authors are appropriately cautious, noting that residual heterogeneity across trials and these nonsignificant subgroup contrasts preclude identification of an optimal exercise prescription.

The biological plausibility underlying these findings is worth emphasizing. Cancer-related fatigue is thought to arise from a convergence of tumor- and treatment-driven inflammation, dysregulation of the hypothalamic-pituitary-adrenal axis, mitochondrial dysfunction, muscle catabolism, and disrupted sleep and mood circuits. Aerobic exercise counteracts several of these pathways simultaneously: regular cardio training lowers circulating pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha over time, improves insulin sensitivity and mitochondrial biogenesis in skeletal muscle, preserves cardiorespiratory fitness that would otherwise decline steeply during chemotherapy, and exerts well-documented antidepressant and anxiolytic effects that indirectly blunt fatigue perception. This multi-system action may explain why exercise outperforms pharmacological approaches in many comparative studies of cancer-related fatigue, and why clinical guidelines from major oncology organizations already recommend physical activity during treatment, even though the specific evidence base for aerobic exercise timed to chemotherapy has been less well quantified until now.

The practical implications for oncology practice are considerable. Chemotherapy is typically delivered over three to six months, a window in which patients often become progressively deconditioned, and in which interventions have historically been deferred on the assumption that patients should conserve energy. The pooled evidence suggests the opposite: the treatment period is precisely when structured aerobic activity can deliver measurable benefit, and doing so is feasible across a range of settings given that the included trials used varied, largely accessible modalities such as walking programs and home-based or supervised cardio. The authors argue that individualized aerobic exercise should be considered an adjunct to supportive oncology care, tailored to each patient’s baseline fitness, treatment regimen, and comorbidities rather than prescribed as a one-size-fits-all regimen. Notably, the review did not highlight safety concerns, though the authors call for future trials to consistently report adherence, achieved exercise dose, safety events, and chemotherapy-related outcomes such as treatment completion and dose intensity, data that remain sparse.

Like all meta-analyses, this one carries caveats. Eleven trials and 933 participants is a meaningful but still modest evidence base, and the authors acknowledge residual heterogeneity among studies, which is expected when interventions differ in intensity, frequency, duration, supervision, and mode, and when fatigue and quality of life are captured with different instruments. Standardized mean differences help bridge those measurement gaps but cannot fully eliminate them. Moreover, because subgroup contrasts were not statistically significant, clinicians and patients should not conclude, for example, that high-intensity interval training is definitively better than moderate continuous walking; rather, the next generation of trials should directly compare these program characteristics head-to-head. The study was prospectively registered on PROSPERO (CRD420261294637) and funded by the Science and Technology Commission of Shanghai Municipality, and the authors declare no competing interests.

Even with those limitations, the takeaway for patients is empowering and refreshingly simple amid a landscape of expensive supportive-care therapies: moving the body during one of the most demanding phases of cancer treatment is safe in the studied settings, achievable, and demonstrably linked to less exhaustion and better quality of life. For clinicians, the findings strengthen the case for embedding exercise physiology into standard oncology workflows, with referral pathways, individualized prescriptions, and supervision structures that make adherence realistic. For researchers, the roadmap is equally clear: rigorous head-to-head trials that specify intensity, format, and supervision, and that report adherence, achieved dose, safety, and chemotherapy outcomes with the same rigor applied to the fatigue and quality-of-life endpoints. As the evidence base matures, the modest but reliable effects quantified here, a reduction in fatigue and a moderate improvement in quality of life, may come to be seen as one of the most cost-effective supportive interventions available to women navigating chemotherapy for breast cancer.

Beyond the headline numbers, the review highlights a broader shift in how supportive cancer care is evaluated. Both endpoints in the analysis were patient-reported outcomes, meaning the benefits were captured directly from patients’ own assessments of their exhaustion and daily functioning rather than from clinician ratings or laboratory measures. This distinction matters, because cancer-related fatigue is inherently subjective and often under-recognized in routine clinic visits, where treatment-related toxicities tend to dominate clinical attention.

The timing of the intervention also deserves attention. Because the included trials initiated aerobic activity during chemotherapy rather than after treatment completion, the findings speak to a period when patients are frequently advised to rest and when physical activity levels typically fall sharply. Demonstrating benefit in this window challenges the long-standing assumption that exertion during active cytotoxic therapy should be minimized.

Finally, the open-access publication and prospective registration on the international trials register reflect growing emphasis on transparency in exercise oncology research, a field where small samples and flexible interventions have historically complicated replication and clinical uptake.

Subject of Research: Aerobic exercise during chemotherapy for reducing cancer-related fatigue and improving quality of life in breast cancer patients.

Article Title: Effects of aerobic exercise during chemotherapy on cancer-related fatigue and health-related quality of life in patients with breast cancer: a systematic review and meta-analysis

Article References: Pang, Z., Zhu, R., Xu, X., Gu, W., & Zhu, D. (2026). Effects of aerobic exercise during chemotherapy on cancer-related fatigue and health-related quality of life in patients with breast cancer: a systematic review and meta-analysis. BMC Cancer. https://doi.org/10.1186/s12885-026-16958-4

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16958-4

Keywords: breast cancer, chemotherapy, aerobic exercise, cancer-related fatigue, health-related quality of life, meta-analysis, systematic review, supportive oncology care, exercise oncology, randomized controlled trials, patient-reported outcomes, exercise prescription